

The evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

Global acceptance and uptake of COVID-19 vaccination, COVID-19 and children, scientific advice in COVID-19 policy, WHO says end is in sight

Peer reviewed journals featured:

- A systematic review on global acceptance and uptake of COVID-19 vaccination [here](#)
- A narrative review on COVID-19 and children [here](#)
- Randomised clinical trials of:
 - COVID-19 prevention and other acute respiratory infections with cod liver oil supplementation [here](#) and associated editorial [here](#)
 - Vilobelimab for critically ill, invasively mechanically ventilated COVID-19 patients [here](#)
 - Withholding methotrexate after Vaxzevria (AstraZeneca) vaccination in patients with rheumatoid or psoriatic arthritis [here](#) and associated commentary [here](#)
 - COVID-19 boosters in non-seroconverted immunosuppressed patients [here](#)
- Observational studies on:
 - Lateral flow test performance in children for SARS-CoV-2 [here](#)
 - Associations of psychological distress prior to SARS-CoV-2 infection with risk of post-COVID-19 conditions [here](#)
 - COVID-19-associated hospitalisations in vaccinated and unvaccinated US adults [here](#)
 - Evaluation of risk factors for post-booster Omicron COVID-19 deaths in England [here](#)
 - Epidemiology and transmission dynamics of the Omicron outbreak in Shanghai [here](#)
 - Initial protection against Omicron in children and adolescents by Comirnaty (Pfizer) in Israel [here](#) and associated commentary [here](#)
 - Comirnaty (Pfizer) and Vaxzevria (AstraZeneca) vaccine effectiveness in people with end-stage kidney disease receiving haemodialysis [here](#)
 - Association of mortality and early tracheostomy in COVID-19 patients [here](#)
 - Early stimulated immune responses and clinical disease severity [here](#)
 - Virological characteristics of the Omicron BA.2 subvariants including BA.4 & BA.5 [here](#)
 - Diagnostic accuracy of COVID-19 rapid antigen tests with unsupervised self-sampling in the Omicron period [here](#) and associated editorial [here](#)
 - Symptom management in people dying with COVID-19 [here](#)
- Commentary on:
 - Role of scientific advice in COVID-19 policy [here](#)
 - COVID-19 lessons learned in migrant-inclusive healthcare delivery [here](#)

Letters and correspondence discussed:

- Fourth dose of mRNA vaccine effectiveness against Omicron in elderly people in Singapore [here](#)
- Effectiveness and durability of Comirnaty (Pfizer) against Omicron sublineages in South Africa [here](#)
- Anti-spike mucosal IgA protection against Omicron infection [here](#)
- Cognitive decline in long-term care residents before and during COVID-19 in Ontario, Canada [here](#)

Pre-peer review articles featured:

- SARS-CoV-2 aerobiology in UK hospitals and the impact of aerosol generating procedures [here](#)
- The effects of COVID-19 on child mental and social health [here](#)
- Long-term impact of COVID-19 on health-related quality of life for people with mild symptoms [here](#)
- Real-world effectiveness of sotrovimab for early treatment of COVID-19 during Delta and Omicron waves in the US [here](#)

Guidance and reports

- The World Health Organization published:
 - Its weekly COVID-19 epidemiological report [here](#)
 - A policy brief on maintaining infection prevention and control measures for COVID-19 in health care facilities [here](#)
- The UK Health Security Health agency published an update on SARS-CoV-2 variants of concern and variants under investigation [here](#)
- The National COVID-19 Clinical Evidence Taskforce released updated recommendations and clinical flowcharts [here](#)
- The Therapeutic Goods Administration (TGA) approved the first combination COVID-19 and influenza self-tests [here](#)

News and blogs

- WHO Director-General says the end of the pandemic is in sight [here](#)
- What scientists have learnt from COVID lockdowns [here](#)
- WHO urges action as 17 million long covid cases are estimated in Europe [here](#)

[Click here](#) to subscribe to, or unsubscribe from, the evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on SARS-CoV-2 [vaccines](#), and [variants](#) of concern, and [post-acute sequelae of COVID-19 \(long COVID\)](#).